Call Us: (513) 621-5112

Sterling Research Blog
Saxenda Recommended for Approval By a Board of FDA Advisors
Friday, July 11, 2014

Another medication Sterling Research is studying has been recommended for approval by a board of FDA advisors as a treatment for weight management. Liraglutide is already FDA approved for the treatment of Diabetes Mellitus Type 2.  It goes by the brand name Victoza.

When it is officially FDA approved, the weight loss therapy will marketed as Saxenda.  It will come as a 3mg dose, delivered subcutaneously.

Obesity is reaching epidemic proportions, and now patients worldwide will have another option in the battle against this disease. Thanks to all of our medical heroes that made this day possible!

-Matt Wenker MD

Subscribe To Our Blog

Blog Categories

  • Articles
  • News
    • 03/28/2016 - Acne: More Than Just Pimples
    • 08/11/2015 - It's Coming...You Know It Is..
    • 02/10/2015 - Attorney General's Office Dema
    • 10/16/2014 - Regeneron, Sanofi drug slashes
    • 10/10/2014 - Ongoing Ebola Epidemic
    • 09/12/2014 - Contrave Approved by the FDA f
    • 07/11/2014 - Saxenda Recommended for Approv
    • 09/04/2013 - Only Half of Hypertensive Adul

Tag Cloud

Call For Participation
Patient Recruitment Specialist
Cincinnati, OH

PH: (513) 621-5112
FX:  (513) 621-5101

Cincinnati / Mt. Auburn
2230 Auburn Avenue
Level B
Cincinnati, OH 45219
PH: (513) 381-4100
FX:  (513) 381-4120

375 Glensprings Drive
2nd Floor
Cincinnati, OH 45246
PH: (513) 671-8080
FX:  (513) 671-8090
New Drug Prevents Heart Attacks in High-Risk Patients
Thursday, March 23, 2017

A new heart drug cuts cholesterol levels to once unthinkable lows, a treatment that doctors hope may prevent future heart attacks or stroke in high-risk patients, according to results from a highly anticipated study released Friday.


Copyright © 2017. STERLING RESEARCH. All Rights Reserved